---  
layout: startup_page  
title: "Aviceda Therapeutics"  
id: "avicedarx.com"  
permalink: "/avicedatherapeuticsavicedarx.com01072025/"  
website: "https://www.avicedarx.com/"  
funding_round: "Series C"  
funding_amount: "$207.5M"  
investors: "Omega Funds, TCGX, Enavate Sciences, Jeito Capital, Longitude Capital, Blue Owl Healthcare Opportunities, OrbiMed, Logos Capital, Marshall Wace, Catalio Capital Management, funds managed by abrdn Inc., Digitalis Ventures"  
about: "Aviceda Therapeutics is a clinical-stage biotech company developing next-generation immunomodulators using a proprietary HALOS™ nanotechnology platform to treat chronic inflammation. Their lead product, AVD-104, targets geographic atrophy, a vision-threatening condition, through a dual mechanism of action. The company aims to provide improved treatment options with enhanced efficacy and safety."  
markets: "Biotechnology, Ophthalmology, Healthcare"  
hq: "Cambridge, Massachusetts, United States"  
founded_year: "2018"  
linkedin: "https://www.linkedin.com/company/aviceda-therapeutics/"  
twitter: "https://twitter.com/avicedarx"  
instagram: ""  
facebook: ""  
crunchbase: "https://www.crunchbase.com/organization/aviceda-therapeutics"  
pitchbook: "https://pitchbook.com/profiles/company/437869-54"  

date_display: "07-Jan-2025"  
date: "2025-01-07"

# SEO Optimization  
meta_title: "Aviceda Therapeutics - Series C Funding ($207.5M)"  
meta_description: "Aviceda Therapeutics, Aviceda Therapeutics is a clinical-stage biotech company developing next-generation immunomodulators using a proprietary HALOS™ nanotechnology platfor..."  
meta_keywords: "Aviceda Therapeutics, Biotechnology, Ophthalmology, Healthcare, Series C funding"  
canonical_url: "https://startup.projectstartups.com/avicedatherapeuticsavicedarx.com01072025/"  
---